SURPASS-CVOT: Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D - Docwire News
Eli Lilly's Tirzepatide has delivered another blockbuster win, with new data from the SURPASS-CVOT trial confirming a significant reduction in Major Kidney Events (MKE) compared to Dulaglutide in patients with Type 2 Diabetes (T2D). This compelling evidence positions Tirzepatide as a frontrunner not just for glucose control and weight management, but also as a critical intervention for renal protection, extending its therapeutic scope beyond current expectations.
















